cancer treatment
treatment of pancreatic cancer
effective small molecule prodrugs
tumour site
generation drug conjugates
tumour regression
targeting tumour cells
standard treatment
target toxicity
targeted cancer therapies
higher therapeutic efficiency
pioneer product SDV1001
generation Antibody Drug Conjugation platform
high efficiency
cancerous cells
Preclinical trials
higher plasma stability
adverse toxicological effects
clinical trials stage
development
controlled release
business model
accounts
issue thanks
commercialization strategy
optimal potential of chemotherapy
new collaborations
formulation
result
reduction
scalable supply chain
highest mortality rate
cancers
partnerships
ones
efficacy
animals
time of diagnosis
patients
patented technologies
Phase
project
Syndivia
years